gene_symbol
HLA-DRB1
hgnc_id
HGNC:4948
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine is taken up by HLA‑DR+ antigen‑presenting cells to present neoantigens and expand neoantigen‑specific CD8+ T cells, which kill tumor cells via perforin/granzyme after MHC I recognition; HLA‑DR itself is not a cytotoxic target.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Peptide-MHC class II presentation to CD4+ T cells; allele-restricted binding
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT03807102
disease_id_num_tar_ref
97
drug_id_num_tar_ref
253